A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 01 Feb 2018 Planned End Date changed from 1 Apr 2023 to 1 Sep 2027.
- 01 Feb 2018 Planned primary completion date changed from 1 Apr 2023 to 1 Sep 2027.
- 09 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.